Top 10 Pharmaceutical Companies in Vietnam 

In the pharmaceutical industry, we are entering a phase where resilience matters more than speed alone. For years, the focus was on how fast a product could reach the market. Today, the conversation has shifted toward who can remain standing and deliver when the global landscape becomes unpredictable. Predictability is no longer a “nice-to-have”; it has become the ultimate competitive advantage. As I shared in my recent post on Linkedin, global BioTech companies are moving away from viewing CDMOs as mere manufacturing vendors. They are seeking strategic anchors — partners capable of ensuring continuity and long-term reliability in uncertain markets. Beyond Transactional Manufacturing The shift we are seeing is a move toward Industrial Diplomacy. It is no longer enough to offer a “corporate brochure” list of services. True partnership requires a disruptive manufacturing narrative that emphasizes expertise and stability over generic volume. When we talk about resilience at Theon, we are looking at four specific pillars: Continuity and Scalability: Being a global manufacturing anchor means having the financial and production stability to absorb supply chain volatility without breaking. Uncompromising Compliance: Quality standards like PICs and EU-GMP are not just badges; they are the foundation of trust required to operate in high-stakes healthcare sectors. Complex Formulation Capabilities: Resilience is also about R&D empathy. We prioritize patient-centricity and the ability to handle complex formulations rather than just chasing simple high-volume orders. Internal Strength: A resilient ecosystem is built from the inside out. Programs like our “Transfer of Wisdom” mentorship ensure we reduce churn and build leadership that can sustain these partnerships for decades. The Future of the Ecosystem The future of pharma manufacturing will be driven by resilient ecosystems, not transactional relationships. We are moving toward a model where the partner’s internal brand strength and technical depth are just as important as their physical output. As we look toward the remainder of 2026, our focus remains on being that reliable anchor. We aren’t just making medicine; we are securing the supply chains that keep global health moving. Amit Bansal Managing Director, Theon Pharmaceuticals Ltd.

Introduction: The Hardware Illusion If you walk the floors of any standard Contract Development and Manufacturing Organization (CDMO) today, the narrative sounds identical: square footage, machine RPMs, and sheer volume. The pharmaceutical manufacturing industry has allowed itself to be commoditized into a hardware business. But when you are tasked with scaling complex, life-saving molecules, treating your manufacturer as a mere “vendor of machinery” is a critical strategic error. At THEON PHARMA, we believe that while anyone with capital can buy a tablet press or a sterile cleanroom, it takes profound intellectual rigor and human empathy to engineer true healthcare. Here is the reality behind manufacturing complex molecules—and the myths we need to leave behind. The 3 Dangerous Myths of Pharma Manufacturing To build an Atmanirbhar supply chain that global brands can trust, we must first dismantle the industry’s most common misconceptions: Myth 1: “Maximum capacity is the ultimate metric of a good CDMO.” The Reality: Scale without uncompromising governance is a liability waiting to happen. Producing volume is easy; producing consistent quality at volume is the real challenge. The THEON Approach: Our Nalagarh facility has the capacity to produce a staggering 2,000 Million tablets annually. But that number is meaningless without our WHO-GMP and EU-GMP compliance frameworks. True manufacturing leadership isn’t just about how fast the machines run; it’s about the “Right & Shared” retention of senior scientists and QA/QC teams who govern those machines to ensure every single tablet is flawless. Myth 2: “Sterile manufacturing just means having a state-of-the-art cleanroom.” The Reality: “Sterile” is not a room; it is a culture of absolute human discipline. The THEON Approach: A critical care patient receiving a sterile injectable has zero margin for error. Behind the 120 Million annual vial/ampoule capacity and ISO Class 5 cleanrooms at our Dera Bassi plant are people who understand the gravity of their work. We train our teams to treat every vial as if it were destined for their own family. The precision of the machine must be driven by the empathy of the human. Myth 3: “Securing the lowest bidder is a strategic procurement win.” The Reality: In the CDMO sector, a race to the bottom on price is a race to compromise patient safety. The lowest bidder is often the highest risk to your brand equity. The THEON Approach: Formulating complex therapies—like heavily segregated Beta-Lactam antibiotics (Penicillins & Cephalosporins) to prevent cross-contamination—is capital-intensive. We fiercely protect our partners by refusing to cut corners to win a price war. We don’t aim to be the cheapest; we aim to be the anchor that geopolitically de-risks your supply chain. The Empathy of R&D: The Story Behind the Molecule Innovation without empathy is just chemistry. Consider the recent success of our DSIR-approved R&D team in securing DCGI permission for the Linagliptin 5mg + Dapagliflozin 10mg tablet. For a standard manufacturer, this is simply a new product code to be processed. For THEON PHARMA, this formulation represents millions of diabetic patients regaining control over their daily lives, their diet, and their longevity. The intricate Phase III clinical success wasn’t just a regulatory hurdle cleared; it was a promise kept to the patient community. When you develop complex molecules for chronic conditions, the manufacturing process cannot be divorced from the patient’s reality. The heartbeat of the patient must dictate the heartbeat of the manufacturing floor. The Assertion: Stop Outsourcing. Start Anchoring. The era of centralized, single-source manufacturing is over. As global pharmaceutical brands look to India to engineer their supply chain resilience for 2026 and beyond, the criteria for choosing a partner must evolve. Do not just audit a facility’s steel and concrete. Audit their heart. Audit their commitment to their people, their environment (like our ISO 14001:2015 certified ETP/STP facilities in Nalagarh), and their unwavering obsession with the patient at the end of the supply chain. THEON PHARMA isn’t just fulfilling contracts; we are engineering the foundation of global healthcare. Partner with the manufacturer that cares as much about your brand—and your patients—as you do.

I’m struggling with the current obsession over automation in the Indian pharma sector. Every week, another CDMO announces a new “fully automated” facility. Zero human intervention. Robotic arms. AI-driven tech transfers. The industry consensus is that if we can just remove the human element, we remove the risk. I disagree with the consensus. I suspect we are just building highly efficient machines that can scale a failed batch faster than ever before. When you scale a manufacturing footprint to handle 120 million sterile liquid vials—like we are currently doing at THEON Lifesciences in Derabassi—the machines aren’t the bottleneck. The machines do exactly what they are told. That is the problem. The Boardroom Friction Last week, we were reviewing the tech transfer for a highly complex, temperature-sensitive CNS formulation. The data from the automated lyophilization cycle looked perfect on the dashboard. It was green across the board. Our senior QA lead halted the transfer anyway. She didn’t like the ambient humidity variance in the staging area just outside the ISO Class 5 cleanroom. The software said it was within acceptable limits. Her ten years of floor experience said it was a disaster waitingto happen. We lost two days of production time running secondary validations. She was right. The software missed a micro-variance that would have triggered a massive OOS (Out of Specification) failure upon commercial scale-up. This is the reality of the CDMO war today. Global drug shortages aren’t happening because we lack compounding tanks. They are happening because USFDA and EMA inspectors are handing out record numbers of Form 483s for ALCOA+ data integrity failures. In 2025 alone, we saw warning letters spike precisely in facilities that over-relied on automated data logging without rigorous human oversight. The “Human Interface” is a Feature, Not a Bug The prevailing myth is that human error is the enemy of sterile manufacturing. Human apathy is the enemy. Human friction is the safeguard. You cannot automate the paranoid, obsessive intuition of a seasoned microbiologist. You cannot write an algorithm that replaces a QC analyst’s willingness to argue with a Plant Head over a marginal test result. As we scale our R&D operations and commercial manufacturing lines this financial year, I am not interested in a frictionless environment. Friction means someone is paying attention. We are investing heavily in what we call the Transfer of Wisdom. It is our internal mentorship architecture. We are deliberately taking our most argumentative, battle-tested senior scientists and pairing them with our new walk-in hires. We aren’t teaching these 24-year-olds how to read an HPLC output. The machine does that. We are teaching them that they hold the absolute authority to stop a 5-million rupee production run if their gut tells them the data doesn’t add up. The Reality of Scale Yes, the “China Plus One” geopolitical shift is pushing unprecedented volume to India. Yes, we have built the 120M vial capacity, the zero-skin-exposure lines, and the PIC/S compliant infrastructure to capture it. But capacity is just steel and code. If you are a Supply Chain Director looking for a CDMO to anchor your FY26 portfolio, stop asking your vendors about their robotic capabilities. Start asking them about their culture of pushback. Ask them how many times their QA department halted production last month. If the answer is zero, walk away. We are scaling our technology. But we are anchoring our survival on the human interface.